Amphetamine pharmacokinetics

Amphetamine pharmacokinetics refers to the physiological processes of absorption, distribution, metabolism, and excretion (ADME) of amphetamine within the human body, rather than a specific molecular target (StatPearls, NBK482503). Amphetamine is a central nervous system stimulant used to treat ADHD and narcolepsy, acting primarily on the Trace amine-associated receptor 1 (TAAR1) and monoamine transporters like the dopamine transporter (DAT) and norepinephrine transporter (NET) (PubChem, CID 3007). Following oral administration, amphetamine is readily absorbed from the gastrointestinal tract and exhibits high bioavailability, with peak plasma concentrations typically reached within a few hours (FDA Label, Adderall). It is metabolized in the liver through various pathways, notably by the enzyme CYP2D6, which converts it into active and inactive metabolites (PubMed, 12661997). A defining characteristic of amphetamine pharmacokinetics is that renal excretion is highly sensitive to urinary pH; acidification of the urine significantly increases the rate of clearance, while alkalization slows it down (StatPearls, NBK482503). Because this term describes a pharmacological profile and the movement of a drug through a biological system rather than a protein, enzyme, or receptor, it is not classified as a therapeutic target. Understanding these pharmacokinetic parameters is essential for clinical dosing, managing drug-drug interactions, and addressing cases of overdose or toxicity.

Other names

Amphetamine ADMEAmphetamine metabolismAmphetamine dispositionAmphetamine clearance

Amphetamine pharmacokinetics is a process, not a target; however, the drug amphetamine acts as an agonist of Trace amine-associated receptor 1 (TAAR1) and an inhibitor/reverser of the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT).